Pharmaceuticals
Eisai-Biogen Alzheimer's drug backed for full U.S. approval
FDA decision on Leqembi expected by July 6
'Made in China' push could help national champions claw away at industry giant
Sustainable loans considered for FDA-approved lecanemab
Hunt for new supplier continues as Beijing keeps research animals on short leash
Cross-border acquisition would be 2nd-biggest in 5 years by a Japanese drugmaker
Drug contains mifepristone, which blocks a pregnancy hormone
Chief Medical Officer Paul Burton highlights room for region-specific shots
Trading house sees growth in Asia for drugs already approved in developed world
Jabs target omicron variants, with 85.3% efficacy from two weeks after booster
Astellas, Eisai and Asahi Kasei follow U.S. lead on lab automation
Growing populations, fewer physicians spur apps like Alodokter, Doctor Anywhere
Japanese drugmaker hopes to hedge risks by producing and selling locally
Number of patients projected to jump 50% by 2045 as dietary habits change
Drugmaker targets capacity of 20m doses yearly, boosting nation's preparedness
Lax stance risks opportunity for 'friend-shoring' to serve Western nations
Treatment would give women option other than surgical procedure
Contaminated over-the-counter medicines killed 300-plus children in 2022
Leqembi's price point spurs optimism after Aduhelm, but wide use unclear
Pandemic saps resources to protect infants from contagious diseases
Structure Therapeutics developing drugs targeting a wide range of chronic diseases
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.